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Automated chest-radiography 
as a triage for Xpert testing in 
resource-constrained settings: a 
prospective study of diagnostic 
accuracy and costs
R. H. H. M. Philipsen1, C. I. Sánchez1, P. Maduskar1, J. Melendez1, L. Peters-Bax2, 
J.G. Peter3, R. Dawson3, G. Theron3, K. Dheda3 & B. van Ginneken1
Molecular tests hold great potential for tuberculosis (TB) diagnosis, but are costly, time consuming, 
and HIV-infected patients are often sputum scarce. Therefore, alternative approaches are needed. We 
evaluated automated digital chest radiography (ACR) as a rapid and cheap pre-screen test prior to 
Xpert MTB/RIF (Xpert). 388 suspected TB subjects underwent chest radiography, Xpert and sputum 
culture testing. Radiographs were analysed by computer software (CAD4TB) and specialist readers, 
and abnormality scores were allocated. A triage algorithm was simulated in which subjects with a 
score above a threshold underwent Xpert. We computed sensitivity, specificity, cost per screened 
subject (CSS), cost per notified TB case (CNTBC) and throughput for different diagnostic thresholds. 
18.3% of subjects had culture positive TB. For Xpert alone, sensitivity was 78.9%, specificity 98.1%, 
CSS $13.09 and CNTBC $90.70. In a pre-screening setting where 40% of subjects would undergo 
Xpert, CSS decreased to $6.72 and CNTBC to $54.34, with eight TB cases missed and throughput 
increased from 45 to 113 patients/day. Specialists, on average, read 57% of radiographs as abnormal, 
reducing CSS ($8.95) and CNTBC ($64.84). ACR pre-screening could substantially reduce costs, 
and increase daily throughput with few TB cases missed. These data inform public health policy in 
resource-constrained settings.
The Xpert® MTB/RIF (Xpert) test (GeneXpert, Cepheid, Sunnyvale, CA, USA) is a promising molecular 
test with great potential for the diagnosis of tuberculosis (TB) with high sensitivity and high specificity1. 
Since its endorsement by the World Health Organization (WHO) in December 2010, over four million 
tests have been procured and the yearly rate of purchased cartridges is increasing2. The costs for Xpert 
have significantly decreased with the help of external funding sources, but remain high ($13–$38)3–11, 
which is a hurdle for resource-constrained settings12. Furthermore, the current scaling up of TB diag-
nostics has created critical funding gaps according to the WHO Global Tuberculosis Report 201313. A 
second disadvantage of the Xpert test is the requirement for a sputum sample. In HIV-endemic regions, 
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this is problematic as many HIV-infected patients are unable to produce sputum14–16. Obtaining spu-
tum from high numbers of subjects is time consuming and logistically challenging, and the majority 
of TB prevalence surveys to date pre-screen participants with symptoms and chest radiography (WHO 
Strategy 3)13,17. Thirdly, the Xpert test involves two hours of processing time, restricting daily through-
put. Thus, high cost and long processing intervals limit the value and widespread uptake of Xpert as a 
point-of-care test. Other widely used tools for the diagnosis of active TB, which are older but reliant, are 
sputum smear microscopy and culture. The former is relatively cheap ($2.10 - $4.60)6,9,11 but has limited 
performance18. The latter is rather expensive ($5 - $15)6,9 and has a processing time of multiple weeks. 
Thus, both tests are suboptimal for the detection of TB in point-of-care settings. Alternative algorithms 
or tests are urgently needed.
Pre-screening tests have the potential to improve throughput if they are quicker to perform than 
Xpert, and should also reduce cost19. In this study, we investigated a novel pre-screening test, namely 
automated chest radiography (ACR), which consists of digital chest radiography assisted by automated 
interpretation by computer software. This test is rapid: it requires only correct positioning of the patient 
to acquire a radiographic image. The image is subsequently processed within 1 minute by a standard 
computer software program. The advantages of automatically analysing radiographs with computer soft-
ware are the need of only a radiographer, and no on-site clinical officer. The latter might not always be 
available and is expensive. ACR is therefore not labour intensive and is faster and potentially cheaper 
than conventional CXR reading. A recent study by Maduskar et al.20 showed that sensitivity and speci-
ficity of computerized reading was not significantly different from reading by clinical officers.
In this study, we evaluate ACR as a pre-screening tool prior to molecular (Xpert) testing. We pro-
pose a diagnostic algorithm that is tested on data from a passive case-finding study, but could also be 
employed in other settings. The performance of this diagnostic algorithm is reported in terms of sensitiv-
ity, specificity, throughput and costs, and is compared with a scenario where Xpert is used for all patients 
and an alternate scenario in which the radiographs are read by humans.
Methods
Data. For this study, data from the TB-NEAT collaborative study was used21. All patients enrolled 
in this study were self-referred TB suspects presenting at a busy urban clinic in Cape Town, South 
Africa. All subjects provided sputum, underwent digital chest radiography on an Odelca DR unit (Delft 
Imaging Systems, Veenendaal, The Netherlands) and were offered voluntary testing and counselling for 
HIV. In the parent study, conventional radiography was used and liquid culture, and Xpert testing was 
performed by a trained laboratory technician in a centralized reference laboratory. Full study details 
have been reported elsewhere21. The study was carried out according to the protocol approved by the 
University of Cape Town Faculty of Health Sciences Research Ethics Committee (#404/2010). All patients 
provided written informed consent for study participation. Of the 419 recruited patients, 6 patients had 
missing radiographs, 22 patients had no conclusive Xpert or culture results and the software was unable 
to ascertain a diagnosis for 3 cases. Thus, a total of 388 patients had all information available. Culture 
positivity for Mycobacterium tuberculosis served as the reference standard. All cases were scored, blinded 
to any clinical information, on an integer scale from 0 to 100 by two CRRS certified “B” readers22,23 and 
an experienced radiologist (reader 3) for the presence of abnormalities consistent with active TB, with a 
score >50 considered suspicious for active TB.
Diagnostic algorithm. All chest X-rays (CXRs) were retrospectively processed by the CAD4TB v3.07 
(Diagnostic Image Analysis Group, Radboud university medical center, Nijmegen, The Netherlands) 
computer software. This software produces a continuous image abnormality score between 0 (normal) 
and 100 (highly abnormal). An example can be found in Fig.  1. Using various thresholds (T) on this 
score, we simulated the effect of using the software as a pre-screening test for molecular testing. In 
this simulated diagnostic algorithm, subjects with a score smaller than or equal to T were regarded as 
TB-negative, and these subjects would not undergo additional testing; otherwise, Xpert test results were 
used. The algorithm is schematically depicted in Fig. 2.
Hypothetical point-of-care testing unit. For this study, we assumed a hypothetical setting where 
a mobile TB unit is used for passive case finding and point-of-care testing. This hypothetical unit would 
have one digital radiography system and three 4-cartridge GeneXpert IV machines, resulting in a capac-
ity of 300 ACRs per day, and an Xpert testing capacity of 45 tests per day. Subjects selected for Xpert 
testing by the ACR pre-screening would be referred directly for Xpert testing in the same unit.
Cost analysis. Cost analysis was limited to the point-of-care-associated costs of diagnosis. We 
assumed an Xpert price of $13.06, based on the FIND subsidized price for Xpert cartridges24. The price 
of ACR is determined largely by the cost of the radiography unit and the throughput. We assume a cost 
of $1.46 for ACR9,25. Furthermore, no increased costs were assumed for manual CXR reading. Detailed 
cost calculations for Xpert and ACR can be found in Table S1 and S2 of the supplementary material.
Performance analysis. Diagnostic performance was assessed by computing sensitivity, specific-
ity, positive predictive value (PPV) and negative predictive value (NPV) at each threshold. With the 
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assumed costs and capacity, the cost per screened subject (CSS), the cost per notified TB case (CNTBC) 
as well as the throughput in cases/day was calculated. The performance of ACR was compared to CXR 
pre-screening with specialist readers. In this scenario, the ACR score was replaced by the composite score 
of specialist readings, and different thresholds (R) were simulated and performance was computed. We 
also evaluated scenarios where all HIV-infected patients would undergo Xpert testing, without receiving 
pre-screening. Sensitivity changes were tested for significance using the McNemar χ 2 test (IBM SPSS 
Statistics 20), considering p < 0.05 significant.
Results
The dataset contained 388 cases, of which 128 (33.0%) subjects were HIV-positive, 71 (18.3%) subjects 
were culture positive, 62 (16.0%) subjects were Xpert positive and 56 (14.4%) subjects were both culture 
and Xpert positive. These results are listed in Table  1. The performance, in terms of area under ROC 
curve, of the CAD4TB software and standalone specialist readers is comparable and not significantly 
different, and is shown in the supplementary Figure S1. Table  2 shows the performance of the ACR 
system at different thresholds. Thresholds were chosen based on the percentage selected for downstream 
Xpert testing shown in the second column. The first row matches the scenario where ACR is omitted and 
every subject receives an Xpert test. The Xpert baseline performance in terms of sensitivity and specificity 
was 78.9% and 98.1%, respectively, resulting in a CSS and CNTBC of $13.09, and $90.70, respectively. 
Significant changes in sensitivity are marked with an asterisk (*). The performance of the diagnostic 
algorithm combined with human reading is shown in Table 3.
Sensitivity and specificity. The maximum achievable sensitivity with this algorithm is that of the 
Xpert test. With increasing ACR score thresholds, more subjects (including TB-positives) were excluded 
for Xpert testing, which by definition decreases sensitivity and increases specificity. The changes in sen-
sitivity and specificity were moderate for scenarios up to T = 85, where 40% of subjects undergo Xpert 
Figure 1. Two example CXRs with corresponding heatmaps. (a) Culture negative CXR with an ACR score 
of 18. (b) Corresponding abnormality heatmap. (c) Culture positive CXR with a subtle abnormality visible 
on the CXR and picked up by the CAD4TB software resulting in an ACR score of 71. (d) Corresponding 
abnormality heatmap. ACR, automated chest radiography; CXR, chest X-ray.
Figure 2. Diagnostic algorithm proposed in this paper. Subjects presenting at a TB screening unit start 
with a pre-screening ACR with a 1-minute computation time to determine whether follow-up Xpert test is 
needed. In the latter case, the Xpert test takes 2 hours to complete. ACR, automated chest radiography; TB, 
tuberculosis; Xpert, Xpert MTB/RIF.
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N (%)
Total 388
Gender
 Male 235 (60.6)
 Female 153 (39.4)
 Mean age (SD) 39.9 (12.0)
HIV status
 positive 128 (33.0)
 negative 252 (64.9)
 unknown 8 (2.1)
Bacteriological findings
 Culture positive 71 (18.3)
 Xpert positive 62 (16.0)
 Culture positive and Xpert positive 56 (14.4)
Table 1.  Study data demographics and statistics. SD, standard deviation.
ACR 
threshold 
T
Selected 
for 
Xpert 
(%)
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
CSS 
($)
CNTBC 
($)
Throughput 
per day
0 100 78.9 98.1 90.3 95.4 13.09 90.70 45
22 90 76.1 98.4 91.5 94.8 13.23 95.09 50
36 80 76.1 99.1 94.7 94.8 11.91 85.64 56
47 70 73.2 99.1 94.5 94.3 10.63 79.36 64
60 60 70.4* 99.1 94.3 93.7 9.32 72.33 75
73 50 70.4* 99.1 94.3 93.7 7.97 61.86 90
85 40 67.6* 99.7 98.0 93.2 6.72 54.34 113
94 30 63.4* 99.7 97.8 92.4 5.34 46.04 150
97 20 49.3* 99.7 97.2 89.8 4.09 45.36 225
Table 2.  Performance results of the proposed diagnostic algorithm with different ACR score thresholds, 
T. The first row matches a scenario where all subjects undergo Xpert and no ACR. Throughputs are based 
on an Xpert capacity of 45/day and an ACR capacity of 300/day. Costs for Xpert and ACR are $13.09 and 
$1.46 respectively. ACR, automated chest radiography; CNTBC, cost per notified TB case; CSS, cost per 
screened subject; NPV, negative predictive value; PPV, positive predictive value; Xpert, Xpert MTB/RIF. 
*Sensitivity significantly different from Xpert standalone, T = 0. (p < 0.05 considered significant).
Reader 
threshold R
Selected for 
Xpert (%)
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
CSS 
($)
CNTBC 
($)
Throughput 
per day
Reader 1 50 63 76.1 98.4 91.5 94.8 9.66 69.40 71
Reader 1 64 32 57.7 99.1 93.2 91.3 5.68 53.73 140
Reader 2 50 56 74.6 99.1 94.6 94.6 8.75 64.04 80
Reader 2 69 31 69.0 99.4 96.1 93.5 5.47 53.15 147
Reader 3 50 53 74.6 99.1 94.6 94.6 8.43 61.07 85
Reader 3 70 28 63.4 99.4 95.7 92.4 5.14 44.30 160
Table 3.  Performance results of the proposed diagnostic algorithm with human reading instead of 
ACR. Throughputs are based on an Xpert capacity of 45/day. For each reader, two thresholds, R, are shown: 
normal/abnormal CXR (R = 50) and a more progressive threshold (~30% Xpert). ACR, automated chest 
radiography; CNTBC, cost per notified TB case; CSS, cost per screened subject; CXR, chest X-ray; NPV, 
negative predictive value; PPV, positive predictive value; Xpert, Xpert MTB/RIF.
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testing: sensitivity decreased to 67.6% and specificity increased to 99.7%. This threshold gave the highest 
sensitivity for the maximal specificity.
PPV and NPV. The PPV started at 90.3% and NPV at 95.4% for the Xpert test. Increasing T leads to 
less false positives and therefore increased the PPV. At the same time, the NPV decreased as there are 
more false negative tests. At T = 85, the PPV has increased to 98.0% and the NPV was 93.2%.
Costs. The CSS and CNTBC for the Xpert test without ACR were $13.09 and $90.70, respectively. For 
conservative thresholds T, these costs increased, because the additional costs to perform ACR on the 
complete population outweighed the costs saved by excluding a small group for Xpert testing. The costs 
saved were dependent on the chosen threshold. For medium-range ACR score thresholds, CSS decreased 
nearly 50%: from $13.09 (T = 0) to $6.72 (T = 85), and the CNTBC decreased nearly 40% from $90.70 
(T = 0) to $54.34 (T = 85). For higher thresholds, the performance decreased substantially with only a 
small decrease in costs.
Throughput. Given the Xpert and ACR capacities, the daily throughput was calculated for each thresh-
old T. The throughput started at 45 for the Xpert-only scenario, and increased to 150 for pre-screening 
with T = 94. The maximum capacity of the digital radiography unit was not reached due to the limited 
Xpert capacity.
Performance analysis stratified by HIV status. The analysis stratified by HIV status, is shown 
in Tables 4 and 5. Comparing the tables, it can be seen that the performance of Xpert was significantly 
better in HIV-uninfected patients than in HIV-infected patients. The HIV-uninfected group showed a 
sensitivity of 93.9% and specificity of 99.1% for Xpert alone, and changed to 87.9% and 100%, respec-
tively, with higher thresholds (T = 85). The CSS and CNTBC decreased 49% and 45%, respectively. The 
sensitivity and specificity of Xpert for HIV-infected subjects was 65.8% and 95.6%, respectively. For 
higher thresholds (T = 85), sensitivity dropped to 50.0% and specificity increased to 98.9% (see Table 5). 
The CSS and CNTBC decreased by 49% and 33%, respectively.
Table 6 shows the results for a scenario where all HIV-infected and HIV-unknown subjects get Xpert 
testing and HIV-uninfected patients get ACR pre-screening. For thresholds up to 50% Xpert (T = 95), the 
performance is better compared to a scenario where all patients get pre-screening. For example, at T = 84 
(60% Xpert), the sensitivity decreased non-significantly to 76.1% and specificity increased to 98.7%, 
while the CSS decreased to $8.81 (33% decrease), CNTBC to $63.30 (30% decrease) and throughput 
increased to 75.
Specialist reading. The results of specialist reading are shown in Table 3. Based on R = 50, the spe-
cialist reader scores associated with suspicion for active TB, three readers committed 63%, 56% and 
53%, respectively, of the cases for Xpert testing. The sensitivity for reader 1 was slightly higher than for 
reader 2 and 3: 76.1% versus 74.6%, but came with a slightly decreased specificity: 98.4% versus 99.1%. 
The PPV for readers 2 and 3 is better than for reader 1: 94.6% versus 91.5%. The NPV was similar for 
all readers, with 94.8% and 94.6%. As reader 2 and 3 sent fewer patients for Xpert testing, the CSS are 
slightly lower, $8.75 and $8.43 versus $9.66, respectively, as are the CNTBC: $64.04 and $61.07 versus 
$69.40, respectively. Comparing these numbers with the ACR threshold T = 60 (see Table 2), which also 
processed roughly 60% of the patients for Xpert, the specialist readers perform marginally better. As the 
ACR 
threshold T
Selected for 
Xpert (%)
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
CSS 
($)
CNTBC 
($)
0 100 93.9 99.1 93.9 99.1 13.09 106.41
24 90 93.9 99.1 93.9 99.1 13.25 107.72
42 80 93.9 99.5 96.9 99.1 11.95 97.16
50 70 93.9 99.5 96.9 99.1 10.60 86.19
67 60 90.9 99.5 96.8 98.6 9.30 78.15
76 50 90.9 99.5 96.8 98.6 8.01 67.24
85 40 87.9 100.0 100.0 98.2 6.71 58.28
93 30 78.8* 100.0 100.0 96.9 5.41 52.41
96 20 69.7* 100.0 100.0 95.6 4.11 45.02
Table 4.  Performance results of the proposed diagnostic algorithm with different ACR score thresholds, 
T, for HIV-uninfected (N = 252) patients only. The first row matches a scenario where all subjects undergo 
Xpert and no ACR. ACR, automated chest radiography; CNTBC, cost per notified TB case; CSS, cost per 
screened subject; NPV, negative predictive value; PPV, positive predictive value; Xpert, Xpert MTB/RIF.  
*Sensitivity significantly different from Xpert standalone, T = 0. (p < 0.05 considered significant).
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radiographs were scored on a scale from 0 to 100, higher thresholds could also be used. For the scenario 
where roughly 30% of the subjects receive Xpert testing, the automated algorithm outperforms reader 1, 
shows similar results for reader 3; however it is inferior to reader 2 (see Table 2).
Discussion
Following WHO recommendations for molecular based testing in 2010, the procurement of the 
GeneXpert MTB/RIF systems in resource-constrained countries is high and is still expanding. However, 
available funds are often limited, and the WHO has also highlighted the need for cost-saving diagnostic 
pathways. Our results have shown that ACR pre-screening may offer a solution: being cheaper, faster, 
with only a moderate decrease in sensitivity, and the benefit of increased throughput, as compared with 
Xpert testing. Using the ACR pre-screening algorithm at T = 85, only 40% of the patients would be sent 
for a downstream Xpert test, and the CSS and CNTBC were less than 51% and 60% of the original cost, 
respectively.
In this study, the benefit of ACR came at the cost of eight additionally missed TB cases. This can 
be attributed to the limitations of radiography screening itself in addition to the use of automated 
pre-screening. Of these eight cases, six were HIV-infected, and it has been previously reported that 
chest radiography is less sensitive in immunocompromised patients26,27. This effect was also seen in the 
results by HIV stratification in Tables  4 and 5. The performance of the diagnostic algorithm among 
HIV-uninfected patients is considerably better than in HIV-infected patients, and consideration should 
ACR 
threshold T
Selected 
for Xpert 
(%)
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%) CSS ($)
CNTBC 
($)
0 100 65.8 95.6 86.2 86.9 13.09 67.02
17 90 60.5 96.7 88.5 85.3 13.22 73.58
35 80 60.5 97.8 92.0 85.4 11.89 66.18
44 70 55.3 97.8 91.3 83.8 10.66 65.00
54 60 52.6* 97.8 90.9 83.0 9.33 59.74
73 50 52.6* 97.8 90.9 83.0 8.01 51.23
85 40 50.0* 98.9 95.0 82.4 6.68 44.97
95 30 44.7* 98.9 94.4 80.9 5.35 40.25
98 20 34.2* 100.0 100.0 78.3 4.12 40.56
Table 5.  Performance results of the proposed diagnostic algorithm with different ACR score thresholds, 
T, for HIV-infected (N = 128) patients only. The first row matches a scenario where all subjects undergo 
Xpert and no ACR. ACR, automated chest radiography; CNTBC, cost per notified TB case; CSS, cost per 
screened subject; NPV, negative predictive value; PPV, positive predictive value; Xpert, Xpert MTB/RIF. 
*Sensitivity significantly different from Xpert standalone, T = 0. (p < 0.05 considered significant).
ACR 
threshold 
T
Selected 
for 
Xpert 
(%)
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
CSS 
($)
CNTBC 
($)
Throughput 
per day
0 100 78.9 98.1 90.3 95.4 13.09 90.70 45
30 90 78.9 98.4 91.8 95.4 12.72 88.15 50
49 80 78.9 98.4 91.8 95.4 11.41 79.04 56
70 70 77.5 98.4 91.7 95.1 10.13 71.43 64
84 60 76.1 98.7 93.1 94.8 8.81 63.30 75
95 50 70.4* 98.7 92.6 93.7 7.49 58.15 90
99 42 59.2* 98.7 91.3 91.5 6.45 59.57 107
100 33 35.2* 98.7 86.2 87.2 5.27 81.75 136
Table 6.  Performance results of the proposed diagnostic algorithm with different ACR score thresholds, 
T, where only HIV-uninfected and HIV-unknown subjects get ACR pre-screening and all HIV-infected 
subjects get Xpert testing. The first row matches a scenario where all subjects undergo Xpert and no ACR. 
ACR, automated chest radiography; CNTBC, cost per notified TB case; CSS, cost per screened subject; NPV, 
negative predictive value; PPV, positive predictive value; Xpert, Xpert MTB/RIF. *Sensitivity significantly 
different from Xpert standalone, T = 0. (p < 0.05 considered significant).
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be applied for different thresholds for both groups. For example pre-screening might be considered 
only for HIV-uninfected patients (Table  6). This would still reduce CSS and CNTBC with more than 
30% (T = 84), with only a marginally non-significant reduction in sensitivity (two additionally missed 
TB cases). Comparing the automated system to specialist readers, the performance of the algorithm is 
slightly inferior with medium-range thresholds, but comparable for high thresholds, although the perfor-
mance among readers differed. However, although not modelled in this study, specialist reading is more 
time consuming, requires training and also increases costs.
The proposed pre-screening diagnostic algorithm is fully automated and requires only an on-site 
radiographer. The availability of automated analysis software obviates the need for a radiologist or clinical 
officer and limits the throughput to that of the radiography unit only. In our simulations, we kept the cost 
of ACR and manual reading constant at $1.46, and this amount did not change with altered throughput 
nor did it affect the main outcomes of the study.
Besides cost-reduction, pre-screening can substantially increase throughput, although it would remain 
limited by the Xpert machine’s capacity. This may be particularly useful in screening settings, as sputum 
collection would not be needed for many potential TB subjects. Additionally, given that the average test 
duration is reduced with most patients receiving a negative radiology test result within a few minutes, 
this would obviate a 2-hour wait for Xpert results.
We predict that, in a typical screening setting, pre-screening with ACR could increase patient 
throughput by up to 250%. Another advantage of automated reading is that different thresholds with 
objective and reproducible results could be chosen. Thus, according to the setting used, a threshold could 
be chosen to obtain the desired sensitivity, specificity or throughput. This makes ACR highly valuable 
in resource-constrained settings, and this proposed diagnostic pathway can save both cost and time in 
a point-of-care setting. We hypothesize that the algorithm’s value is even higher in active case-finding 
scenarios and sputum-scarce cohorts, but future studies are needed.
Compared to a recent study by Muyoyeta et al.28, which uses a previous version of the CAD4TB 
software on presumptive TB patients with Xpert as reference, the current software showed improved 
performance and supported their findings that ACR has a potential role in TB screening. Additionally, 
the current software showed better performance values than reported in a previous study by Maduskar 
et al.20.
The proposed diagnostic algorithm does not account for patients with high ACR scores but negative 
Xpert results: it is likely that these patients either have a false negative Xpert test or may have disease 
other than TB. Furthermore, current costs analysis was limited to the costs of diagnosis only and does 
not take into account the cost of treatment and misdiagnosed patients. This group of patients should be 
flagged to receive further attention based on their ACR scores. In general, basic automated screening for 
abnormalities could prompt referral mechanisms for higher levels of care.
In conclusion, ACR pre-screening before sputum Xpert molecular testing is a promising new advance 
in TB diagnostics. The ACR algorithm can significantly reduce cost and substantially increase through-
put, while maintaining high sensitivity. This makes it a potentially highly valuable diagnostic tool in 
resource-constrained countries.
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